Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

Most common central nervous system disorders — such as depression, bipolar disorder and schizophrenia — seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies. Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single molecular targets (that is, 'magic bullets') have, not surprisingly, been largely unsuccessful. Here we propose that designing selectively non-selective drugs (that is, 'magic shotguns') that interact with several molecular targets will lead to new and more effective medications for a variety of central nervous system disorders.

[1]  R. Mowbray,et al.  HALLUCINOGENS , 1970, The Medical journal of Australia.

[2]  Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioral studies. , 1982, European journal of pharmacology.

[3]  G. Fischer,et al.  [Psychiatry in the press]. , 1983, Das Offentliche Gesundheitswesen.

[4]  C. Altar,et al.  Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain , 1986, Brain Research Bulletin.

[5]  B. Roth,et al.  Multiple mechanisms of serotonergic signal transduction. , 1987, Life sciences.

[6]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[7]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[8]  BMY 14802, a Sigma Receptor Ligand for the Treatment of Schizophrenia , 1994, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[9]  H. Wetzel,et al.  Dopamine agonists in schizophrenia: a review , 1995, European Neuropsychopharmacology.

[10]  S. Morita,et al.  7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. , 1995, The Journal of pharmacology and experimental therapeutics.

[11]  K. Yamada,et al.  Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. , 1996, The Journal of pharmacology and experimental therapeutics.

[12]  H. Westenberg,et al.  Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients , 1996, Biological Psychiatry.

[13]  F. Lang,et al.  Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole , 1996, FEBS letters.

[14]  A. Getson,et al.  The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. , 1997, Archives of general psychiatry.

[15]  C. Ragan,et al.  Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. , 1997, Trends in pharmacological sciences.

[16]  D. Wong,et al.  Correction: a note on the discovery of selective serotonin reuptake inhibitors. , 1997, Life sciences.

[17]  V. Pérez,et al.  Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment , 1997, The Lancet.

[18]  C. Tamminga,et al.  Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia , 1998, Journal of Neural Transmission.

[19]  C. Tamminga,et al.  Antipsychotic Properties of the Partial Dopamine Agonist (−)-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia , 1998, Biological Psychiatry.

[20]  H. Hippius.  A historical perspective of clozapine. , 1999, The Journal of clinical psychiatry.

[21]  A. Anand,et al.  The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial , 1999, Biological Psychiatry.

[22]  H. Meltzer,et al.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.

[23]  Matthias J. Müller,et al.  Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial , 1999, Psychiatry Research.

[24]  L. Fabre,et al.  Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. , 1999, The American journal of psychiatry.

[25]  David R. Sibley,et al.  Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.

[26]  P. Goldman-Rakic,et al.  Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. , 2000, Science.

[27]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[28]  The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance , 2001, Schizophrenia Research.

[29]  D. Allison,et al.  Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate , 2001, Psychiatry Research.

[30]  A. Sleight,et al.  A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze , 2001, Neuropharmacology.

[31]  J. Feighner,et al.  Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression , 2001, International clinical psychopharmacology.

[32]  I. Anderson,et al.  Meta-analytical studies on new antidepressants. , 2001, British medical bulletin.

[33]  T. dePaulis.  M-100907 (Aventis). , 2001 .

[34]  SB-277011 GlaxoSmithKline. , 2001, Current opinion in investigational drugs.

[35]  M. Thase,et al.  Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors , 2001, British Journal of Psychiatry.

[36]  T. de Paulis.  M-100907 (Aventis). , 2001, Current opinion in investigational drugs.

[37]  Terry Kenakin,et al.  Efficacy at g-protein-coupled receptors , 2002, Nature Reviews Drug Discovery.

[38]  J. Kane,et al.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. , 2002, The Journal of clinical psychiatry.

[39]  John Bohannon,et al.  Can a Mouse Be Standardized? , 2002, Science.

[40]  P. Goldman-Rakic,et al.  The Physiological Role of 5-HT2A Receptors in Working Memory , 2002, The Journal of Neuroscience.

[41]  D. Goff,et al.  d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia , 2002, Schizophrenia Research.

[42]  E. Shorter.  Looking backwards: a possible new path for drug discovery in psychopharmacology , 2002, Nature Reviews Drug Discovery.

[43]  Richard Entsuah,et al.  Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression , 2002, Biological Psychiatry.

[44]  J. Amsterdam,et al.  A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A—a putative, new antidepressant , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[45]  S. Gilbody,et al.  Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials , 2002, Schizophrenia Research.

[46]  Kevin D Burris,et al.  Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.

[47]  Animal models. Can a mouse be standardized? , 2002, Science.

[48]  Eric Nestler,et al.  In need of high-throughput behavioral systems. , 2002, Drug discovery today.

[49]  C. Altar,et al.  Novel directions in antipsychotic target identification using gene arrays. , 2002, Current drug targets. CNS and neurological disorders.

[50]  Bryan L Roth,et al.  G-protein-coupled receptors at a glance , 2003, Journal of Cell Science.

[51]  Steven G Potkin,et al.  Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’? , 2003, Clinical Neuroscience Research.

[52]  M. Briley.  New hope in the treatment of painful symptoms in depression. , 2003, Current opinion in investigational drugs.

[53]  S. Leucht,et al.  New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis , 2003, The Lancet.

[54]  V. Setola,et al.  Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants. , 2003, Molecular pharmacology.

[55]  R. Hen,et al.  Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants , 2003, Science.

[56]  Paul J. Harrison,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Genes for Schizophrenia? Recent Findings and Their Pathophysiological Implications , 2022 .

[57]  Leena Peltonen,et al.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. , 2003, American journal of human genetics.

[58]  Alan I Green,et al.  Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). , 2003, Archives of general psychiatry.

[59]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[60]  B. Maher,et al.  Genome‐wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early‐onset, major depression , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[61]  F. Colpaert.  Discovering risperidone: the LSD model of psychopathology , 2003, Nature Reviews Drug Discovery.

[62]  J. Coyle,et al.  Finding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments , 2003, Neuron.

[63]  John R. Geddes,et al.  Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis , 2003, The Lancet.

[64]  Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors , 2003, Schizophrenia Research.

[65]  Paul Ernsberger,et al.  H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[66]  H. Meltzer,et al.  Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. , 2004, The American journal of psychiatry.